Global Regulatory News and Updates

Welcome to Carver's regulatory updates podcast for the week of April 12, 2026.

Starting with Switzerland, the Swiss Federal Food Safety and Veterinary Office, known as BLV, has issued a public warning regarding Salmonella contamination in various soft cheeses. The affected products are sold by retailers including Coop and Migros. Käserei Landbrück has initiated a recall of these cheeses. Consumers are strongly advised not to consume the affected products and to seek medical advice if they experience symptoms after consumption. Retailers and producers must remove these products from sale and conduct recalls promptly to protect public health.

In the Czech Republic, a draft list titled "Návrh Seznamu cen a úhrad PZLÚ" has been published, detailing manufacturer prices, maximum prices, reimbursement amounts, and conditions for foods for special medical purposes. These changes are set to take effect from January 1, 2026. The draft includes a 12 percent value-added tax rate applied to these products. Manufacturers, importers, and healthcare payers under Czech public health insurance regulations must adhere to the new pricing and reimbursement conditions. Stakeholders are invited to submit comments on the draft list by April 20, 2026, via the designated email address.

Moving to the Netherlands, the Dutch Healthcare and Youth Inspectorate, IGJ, has issued a formal administrative directive to Derman Woonzorg in De Steeg. Due to serious risks in care quality and safety, Derman Woonzorg is required to transfer its clients to other care providers within four weeks. Derman Woonzorg may only resume care services once the IGJ confirms compliance with care standards.

In the United States, specifically Texas, the Texas Comptroller’s Office has reminded businesses that April 15 is the deadline for filing property tax renditions. Businesses must file these renditions annually to ensure accurate property tax assessments. Additionally, special decreased value reports can be filed for property damaged in 2025 to potentially reduce 2026 tax bills. The necessary forms are available from county appraisal districts or the Comptroller’s property tax forms webpage.

Also in the United States, the Securities and Exchange Commission, or S-E-C, has barred Danny M. Salinas and Mai T. Nguyen from association with broker-dealers, investment advisers, municipal securities dealers, municipal advisors, transfer agents, or nationally recognized statistical rating organizations. This action follows findings of fraudulent conduct in unregistered securities sales. Any application for reentry into the securities industry must comply with applicable laws and may require payment of disgorgement, civil penalties, arbitration awards, or restitution.

On a global scale, the World Health Organization has updated its guidelines on opioid dependence treatment and overdose prevention. The updated recommendations reaffirm opioid agonist maintenance treatment with methadone and oral buprenorphine. Additionally, there is a new conditional recommendation for long-acting injectable buprenorphine formulations. These treatments should be administered by accredited professionals within recognized medical practice.

In the United States, Nacha has announced that its Automated Clearing House, or A-C-H, Rules will tighten in 2026. This increases the importance of account validation as a tool to maintain compliance and reduce fraud and return rates in electronic payments. Organizations are required to meet and maintain Nacha WEB debit compliance, use real-time non-credentialed bank-account intelligence for fraud reduction, and gain visibility into account activity, return history, and account age.

Turning to Indonesia, the National Agency of Drug and Food Control, known as BPOM, has approved the use of measles vaccines for adults. These include Measles-Rubella, Measles-Mumps-Rubella, and Measles single vaccines. The approval covers healthcare workers, international travelers, and other high-risk groups following comprehensive scientific evaluation.

In Italy, the reimbursement and monitoring framework for CARVYKTI, or ciltacabtagene autoleucel, has been formalized. CARVYKTI is now reimbursable for adult patients with relapsed and refractory multiple myeloma who meet specific clinical criteria. A dedicated monitoring registry has been established, and access to the Innovative Drug Fund is guaranteed. Prescriptions must comply with eligibility and appropriateness criteria outlined in the clinical sheet. Healthcare centers must be authorized and enabled on the web platform to use the registry.

That wraps up today's regulatory updates. Visit carveragents.ai for more information.